Volume 65, Issue 3, Pages (March 2014)

Slides:



Advertisements
Similar presentations
The PSA Era is not Over for Prostate Cancer
Advertisements

Results of Targeted Biopsy in Men with Magnetic Resonance Imaging Lesions Classified Equivocal, Likely or Highly Likely to Be Clinically Significant Prostate.
Volume 71, Issue 6, Pages (June 2017)
Volume 69, Issue 3, Pages (March 2016)
Volume 59, Issue 2, Pages (February 2011)
Contemporary Clinical Trials
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Volume 66, Issue 1, Pages (July 2014)
Testosterone Therapy in Men With Prostate Cancer
Volume 56, Issue 6, Pages (December 2009)
Volume 61, Issue 6, Pages (June 2012)
Volume 52, Issue 4, Pages (October 2007)
Volume 63, Issue 1, Pages (January 2013)
Volume 67, Issue 3, Pages (March 2015)
Volume 58, Issue 1, Pages (July 2010)
European Urology Oncology
Dynamic Contrast-Enhanced MRI for Preoperative Identification of Localised Prostate Cancer  Arnauld Villers, Philippe Puech, Xavier Leroy, Jacques Biserte,
Prostate Cancer Epidemic in Sight?
Volume 65, Issue 6, Pages (June 2014)
Volume 61, Issue 3, Pages (March 2012)
Volume 66, Issue 1, Pages (July 2014)
The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.
Volume 63, Issue 6, Pages (June 2013)
Volume 69, Issue 3, Pages (March 2016)
Volume 62, Issue 3, Pages (September 2012)
European Urology Oncology
Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal.
Prostate Cancer Detection: A View of the Future
Volume 62, Issue 1, Pages (July 2012)
Marcel J. Steggerda, Henk G. van der Poel, Luc M.F. Moonen 
Volume 199, Issue 4, Pages e768-e769 (April 2018)
Volume 69, Issue 6, Pages (June 2016)
Volume 67, Issue 4, Pages (April 2015)
Prostate Imaging-Reporting and Data System Steering Committee: PI-RADS v2 Status Update and Future Directions  Anwar R. Padhani, Jeffrey Weinreb, Andrew.
Prostate Cancer Epidemic in Sight?
The PSA Era is not Over for Prostate Cancer
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Volume 61, Issue 6, Pages (June 2012)
Volume 68, Issue 6, Pages (December 2015)
Volume 53, Issue 6, Pages (June 2008)
Volume 54, Issue 3, Pages (September 2008)
Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia
Volume 65, Issue 6, Pages (June 2014)
Tillmann Loch, Pat Fox Fulgham  European Urology 
Volume 68, Issue 4, Pages (October 2015)
Clinical Utility of Multiparametric Magnetic Resonance Imaging as the First-line Tool for Men with High Clinical Suspicion of Prostate Cancer  Valeria.
Volume 65, Issue 4, Pages (April 2014)
Volume 68, Issue 6, Pages (December 2015)
Volume 66, Issue 3, Pages (September 2014)
Volume 65, Issue 1, Pages (January 2014)
Volume 50, Issue 5, Pages (November 2006)
CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System
Volume 55, Issue 3, Pages (March 2009)
European Urology Oncology
Testicular Cancer Variations in Time and Space in Europe
Volume 75, Issue 4, Pages (April 2019)
Volume 73, Issue 1, Pages (January 2018)
The SmartTarget Biopsy Trial: A Prospective, Within-person Randomised, Blinded Trial Comparing the Accuracy of Visual-registration and Magnetic Resonance.
European Urology is “Your” Journal
Jonathan S. Brajtbord, Michael S. Leapman, Matthew R. Cooperberg 
Volume 66, Issue 1, Pages (July 2014)
Nandita M. deSouza, Veronica A. Morgan, Elizabeth Bancroft, S
Prostate Cancer Screening Decreases the Absolute Risk of Being Diagnosed with Advanced Prostate Cancer—Results from a Prospective, Population-Based Randomized.
Role of Transurethral Resection of the Prostate and Biopsy of the Peripheral Zone in the Same Session after Repeated Negative Biopsies in the Diagnosis.
Volume 69, Issue 1, Pages (January 2016)
The Role of Systematic and Targeted Biopsies in Light of Overlap on Magnetic Resonance Imaging Ultrasound Fusion Biopsy  Neal Patel, Eliza Cricco-Lizza,
Not All Multiparametric Magnetic Resonance Imaging–targeted Biopsies Are Equal: The Impact of the Type of Approach and Operator Expertise on the Detection.
Systematic Review of Complications of Prostate Biopsy
European Urology Oncology
Introduction European Urology Supplements
Presentation transcript:

Volume 65, Issue 3, Pages 628-634 (March 2014) Prostate Cancer Risk Inflation as a Consequence of Image-targeted Biopsy of the Prostate: A Computer Simulation Study  Nicola L. Robertson, Yipeng Hu, Hashim U. Ahmed, Alex Freeman, Dean Barratt, Mark Emberton  European Urology  Volume 65, Issue 3, Pages 628-634 (March 2014) DOI: 10.1016/j.eururo.2012.12.057 Copyright © 2012 Terms and Conditions

Fig. 1 All-cancer sensitivity of biopsy simulations with increasing error. European Urology 2014 65, 628-634DOI: (10.1016/j.eururo.2012.12.057) Copyright © 2012 Terms and Conditions

Fig. 2 Simulated 12-core transrectal ultrasound biopsy. Correct anatomic position and orientation estimated using T2-weighted magnetic resonance imaging (1.5 T). Three-dimensional coordinates taken from the centre of the anus and gland, and aligned with the base-apex axis. Coordinates were used to approximate the variability in the probe/needle insertion location and trajectory during simulated biopsies. Simulated needle insertions were automatically calculated by computer software, so the conduct of the biopsies was fully blinded to the pathology. European Urology 2014 65, 628-634DOI: (10.1016/j.eururo.2012.12.057) Copyright © 2012 Terms and Conditions

Fig. 3 Simulated targeted biopsy. Using a 5-mm brachytherapy template, visible urethra was aligned to the D 2.0 grid coordinate on midgland transverse view. Planned positions of the targeted cores (1–5) were optimised so that the total cancer core length obtained was maximised. European Urology 2014 65, 628-634DOI: (10.1016/j.eururo.2012.12.057) Copyright © 2012 Terms and Conditions

Fig. 4 Detection of all cancer, and clinically significant disease, using 12-core transrectal ultrasound (TRUS) biopsy and a 3- or 4-core targeted strategy. CCL=cancer core length. European Urology 2014 65, 628-634DOI: (10.1016/j.eururo.2012.12.057) Copyright © 2012 Terms and Conditions